Skip to main content

Takhzyro Side Effects

Generic name: lanadelumab

Medically reviewed by Philip Thornton, DipPharm. Last updated on May 12, 2022.

Note: This document contains side effect information about lanadelumab. Some dosage forms listed on this page may not apply to the brand name Takhzyro.

Applies to lanadelumab: subcutaneous solution.

Serious side effects of Takhzyro

Along with its needed effects, lanadelumab (the active ingredient contained in Takhzyro) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking lanadelumab:

More common

  • Rash

Less common

  • Fast heartbeat
  • fever
  • hives, itching
  • hoarseness
  • irritation
  • joint pain, stiffness, or swelling
  • redness of the skin
  • swelling of the eyelids, face, lips, hands, or feet
  • tightness in the chest
  • troubled breathing or swallowing

Other side effects of Takhzyro

Some side effects of lanadelumab may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

  • Bleeding, blistering, burning, coldness, discoloration of skin, feeling of pressure, hives, infection, inflammation, itching, lumps, numbness, pain, rash, redness, scarring, soreness, stinging, swelling, tenderness, tingling, ulceration, or warmth at the injection site
  • body aches or pain
  • chills
  • cough
  • difficulty in moving
  • dizziness
  • ear congestion
  • headache
  • loss of voice
  • muscle ache, cramps, pain, or stiffness
  • nasal congestion
  • runny nose
  • sneezing
  • sore throat
  • unusual tiredness or weakness

Less common

For Healthcare Professionals

Applies to lanadelumab: subcutaneous solution.


The most common adverse reactions were injection site reactions, upper respiratory infection, headache, rash, myalgia, dizziness, and diarrhea.[Ref]


Very common (10% or more): Upper respiratory infection (up to 44%)

Frequency not reported: Viral upper respiratory infection[Ref]

Nervous system

Very common (10% or more): Headache (up to 33%), dizziness (up to 10%)

Frequency not reported: Tension headache, sinus headache[Ref]


Very common (10% or more): Anti-drug antibody (ADA)-positive sample during treatment with this drug (12%)

Common (1% to 10%): Hypersensitivity[Ref]


Very common (10% or more): Myalgia (up to 11%)[Ref]


Very common (10% or more): Diarrhea (up to 11%)[Ref]


Common (1% to 10%): ALT increased, AST increased, ALT or AST greater than 8 times the upper limit of normal[Ref]


Very common (10% or more): Injection site reactions (up to 56%)

Frequency not reported: Pain, erythema, bruising, hematoma, hemorrhage, pruritus, swelling, induration, paresthesia, warmth, edema, rash[Ref]


Very common (10% or more): Rash (up to 10%)

Frequency not reported: Maculopapular rash, erythematous rash[Ref]

Frequently asked questions


1. "Product Information. Takhzyro (lanadelumab)." Dyax Corporation (2018):

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.